CD274 and cancer: Another potential explanation for the observed differences could be the Fc effector function of avelumab: unlike atezolizumab and durvalumab, avelumab is the only PD-L1 blocker with a non-silenced Fc and this may influence its efficacy in certain types of cancer [34].